AUTHOR=Ortiz-Maldonado Valentín , Frigola Gerard , Español-Rego Marta , Balagué Olga , Martínez-Cibrián Nuria , Magnano Laura , Giné Eva , Pascal Mariona , Correa Juan G. , Martínez-Roca Alexandra , Cid Joan , Lozano Miquel , Villamor Neus , Benítez-Ribas Daniel , Esteve Jordi , López-Guillermo Armando , Campo Elías , Urbano-Ispizua Álvaro , Juan Manel , Delgado Julio 

TITLE=Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.828471

DOI=10.3389/fonc.2022.828471

ISSN=2234-943X

ABSTRACT=<p>CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.</p>